The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Completed · Phase 3

Conditions studied: Chronic Obstructive Pulmonary Disease, COPD

In brief

The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.

Key facts

Study ID

NCT00108823

Run by

AstraZeneca

People needed

550

Starts

2004-10-01

Last updated by the study team

2016-10-26

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• ALTANA Pharma — Cities in California, California, United States
• ALTANA Pharma — Cities in Colorado, Colorado, United States
• ALTANA Pharma — Cities in Florida, Florida, United States
• ALTANA Pharma — Cities in Missouri, Missouri, United States
• ALTANA Pharma — Cities in New Mexico, New Mexico, United States
• ALTANA Pharma — Cities in New York, New York, United States
• ALTANA Pharma — Cities in Oregeon, Oregon, United States
• ALTANA Pharma — Cities in South Carolina, South Carolina, United States
• ALTANA Pharma — Cities in Texas, Texas, United States
• ALTANA Pharma — Cities in Washington, Washington, United States
• ALTANA Pharma — Cities in Canada, Canada
• ALTANA Pharma — Cities in France, France
• ALTANA Pharma — Cities in Poland, Poland
• ALTANA Pharma — Cities in South Africa, South Africa
• ALTANA Pharma — Cities in Spain, Spain
• ALTANA Pharma — Cities in the United Kingdom, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.